Last Updated : March 16, 2015
The Canadian Agency for Drugs and Technologies in Health (CADTH) examined the clinical and economic impact of new and existing drugs to treat pulmonary arterial hypertension (PAH).
The review included drugs that are currently available in Canada, and those that are newly emerging and not yet approved in Canada.
The project had two key components:
The impending availability of new drugs for the treatment of PAH could have a significant impact on treatment strategies. By reviewing the evidence and developing reports and tools, CADTH provides health care decision-makers with the evidence-based resources they need to make informed decisions.
The Canadian Agency for Drugs and Technologies in Health is piloting the inclusion of patient group input in its process for the therapeutic review of drugs for pulmonary arterial hypertension.
The submitted patient group input identifies health outcomes and issues of importance to patients, and their unmet needs in managing pulmonary arterial hypertension. The patient input is systematically incorporated into this therapeutic review, beginning with informing the project protocol through to informing the Canadian Drug Expert Committee in making its recommendation(s) based on this therapeutic review.
Below are links to the patient group input that was submitted for this project. Documents have not been summarized, edited, or critically appraised — they are posted in the format in which they were received.